Roivant posted a GAAP net loss of USD 290.61 million, widening from USD 273.91 million a year earlier; GAAP loss per share improved to USD 0.26 from USD 0.33.
GAAP revenue slipped to USD 1.44 million from USD 2.17 million; GAAP R&D expense rose to USD 202.02 million from USD 152.92 million.
GAAP G&A expense increased to USD 165.53 million from USD 134.02 million, largely on higher personnel costs tied to the Moderna settlement.
Non-GAAP net loss widened to USD 243.69 million from USD 170.12 million; non-GAAP R&D climbed to USD 192.95 million from USD 141.03 million.
Cash position and outlook
Cash, cash equivalents, restricted cash and marketable securities totaled USD 3.9 billion; brepocitinib launch in dermatomyositis targeted by end-September 2026.
ROIV•
